Last reviewed · How we verify

NCT04674397: BONES

BOne Dysfunction in Donor NEphrectomieS

Completed Last updated 7 December 2021
What this trial tests

trial testing Radioisotope GFR test in Renal Failure in 34 participants. Completed in 1 August 2020.

Timeline
29 July 2015
Primary endpoint
1 August 2020
1 August 2020

Quick facts

Lead sponsorManchester University NHS Foundation Trust
StatusCompleted
Study typeOBSERVATIONAL
Enrollment34
Start date29 July 2015
Primary completion1 August 2020
Estimated completion1 August 2020
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Manchester University NHS Foundation Trust

Who can join

Adults 18 to 80, any sex, with Renal Failure or Kidney Donors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Most dialysis patients die from vascular disease, which is statistically associated with changes related to chronic kidney disease associated mineral bone disorder (CKD-MBD)3-9. Understanding the mechanisms behind this high death rate is crucial to improving the length and quality of life for patients with all grades of kidney disease, including those on dialysis. This is a priority for patients and clinicians alike. Most humans with early CKD are asymptomatic and unaware that they have a problem with their kidneys. Therefore they are unlikely to consult a doctor and early CKD is often unrecognised. Patients who are aware of early CKD often have other co-morbidities including diabetes, hypertension and vascular disease which, in the setting of a clinical study, complicate the identification of changes solely resulting from CKD. However over the past decade living kidney donation has become increasingly common and is now the source of organs for more than 120 patients annually at Manchester's renal transplant centre. Prospective donors are carefully examined and known to have normal kidney function without other co-morbidities. They then undergo a planned unilateral nephrectomy and lose approximately 50% of their kidney mass, creating an immediate state of moderate CKD. Over subsequent months the remaining kidney will hypertrophy and partially correct this, although the mechanisms are unknown. In the immediate post-operative period donors are inpatients on the kidney transplant ward and have regular blood and urine tests meaning that careful study of metabolic processes during their recovery is relatively easy by analysis of serial plasma and urine samples. Sequential changes in the plasma and urine levels of different bone turnover markers and metabolites can be analysed and will provide valuable new information to increase our understanding of the initial stage of CKD-MBD development.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Renal Failure

Currently open trials in the same condition.

Other Manchester University NHS Foundation Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04674397.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing